Drug Trial Radar · NCT04478279
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
125
Actual
Start
Jul 1, 2020
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Sapience TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Conditions
- Glioblastoma
- Melanoma Stage IV
- Breast Cancer
- Prostate Cancer
- Glioblastoma Multiforme
- GBM
- Brain Cancer
- Metastatic Breast Cancer
- Metastatic Melanoma
- Metastatic Prostate Cancer
- Melanoma Recurrent
- Prostate Cancer Metastatic
- Recurrent Glioblastoma
- Newly Diagnosed Glioblastoma
Interventions
ST101Drug
ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
TemozolomideDrug
Temozolomide
RadiationRadiation
Radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT)Time frame: 20 months
- Adverse EventsTime frame: 20 months
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Sarah Cannon Research Institute
Denver, Colorado
Northwestern Medicine Cancer Centers
Warrenville, Illinois
START Midwest
Grand Rapids, Michigan
Columbia University
New York, New York
Duke University School of Medicine
Durham, North Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Edinburgh Cancer Centre
Edinburgh, United Kingdom
The Beaston West of Scotland Cancer Centre
Glasgow, United Kingdom
University of Leeds
Leeds, United Kingdom
Sarah Cannon Research Institute UK
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.